Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q1 2026 Earnings Call Transcript
Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc. (ARCT)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Squarepoint Ops LLC Maxime Fortin (Cio) | 21,344 | $292,199 | -58% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $16.56 | 1,238 | $20,498.80 | 221,764 | 2025-08-15 | Filing | |
| $16.56 | 1,238 | $20,498.80 | 221,764 | 2025-08-15 | Filing | |
| $18.00 | 2,222 | $39,996.00 | 24,942 | 2022-12-15 | Filing | |
| $16.51 | 5,000 | $82,550.00 | 1,480,097 | 2022-11-23 | Filing | |
| $33.33 | 450 | $14,998.50 | 950 | 2020-06-12 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.76 | 12,000 | $249,121.20 | 435,334 | 2024-10-15 | Filing | |
| $32.03 | 50,000 | $1,601,500.00 | 220,526 | 2024-06-12 | Filing | |
| $45.00 | 114 | $5,130.00 | 447,334 | 2024-06-05 | Filing | |
| $40.01 | 26,000 | $1,040,234.00 | 447,448 | 2024-06-03 | Filing | |
| $35.02 | 17,435 | $610,573.70 | 473,448 | 2024-03-25 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,689,107 | $23,123,875 | 0.01% | |
| 2. | 620,103 | $8,491,196 | 0% | |
| 3. | 365,462 | $5,003,175 | 0.27% | |
| 4. | 349,102 | $4,779,206 | 0.14% | |
| 5. | 218,023 | $2,984,754 | 0% |
News See All
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2025 Earnings Call Transcript
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2025 Earnings Call Transcript March 3, 2026Arcturus Therapeutics Holdings Inc. misses on earnings expectations.
Citi Lowers Price Target on Arcturus Therapeutics Holdings Inc. (ARCT) to $7, Maintains Neutral Rating
We recently published an article titled 11 High Growth Micro-cap Stocks to Buy. On January 6, Citi lowered its price target on Arcturus Therapeutics Holdings Inc.
11 High Growth Micro-cap Stocks to Buy
In this article, we will discuss 11 High Growth Micro-cap Stocks to Buy.
Roth Capital Say Market Pricing Implies Zero Success for Arcturus Therapeutics Holdings Inc. (ARCT) Pipeline Assets
We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. The seventeenth stock on our list is Arcturus Therapeutics Holdings Inc.
20 Best Biotech Stocks Under $20 to Buy Now
In this article, we will be taking a look at the 20 Best Biotech Stocks Under $20 to Buy Now. The U.S.
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q3 2025 Earnings Call Transcript
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q3 2025 Earnings Call Transcript November 10, 2025Arcturus Therapeutics Holdings Inc. beats earnings expectations.
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q2 2025 Earnings Call Transcript
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q2 2025 Earnings Call Transcript August 11, 2025Arcturus Therapeutics Holdings Inc. beats earnings expectations.
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q1 2025 Earnings Call Transcript
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q1 2025 Earnings Call Transcript May 12, 2025Arcturus Therapeutics Holdings Inc. beats earnings expectations.
10 Worst High-Risk High-Reward Growth Stocks To Buy
In this article, we will look at the 10 Worst High-Risk High-Reward Growth Stocks To Buy.
Hedge Fund Resource Center